Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1681888 | 0.99 | ACHE (0.63) | ACHE | |
| SCHEMBL1682090 | 0.90 | ACHE (0.52) | ACHE | |
| Hydrochloric Acid SCHEMBL1681811 | 0.89 | ACHE (0.51) | ACHE | |
| SCHEMBL7226350 | 0.80 | ACHE (0.81) | ACHE | |
| SCHEMBL1681970 | 0.79 | ALDH1A1 (0.61) | ACHE | |
| SCHEMBL4512070 | 0.78 | ACHE (1.00) | ACHE | |
| Hydrochloric Acid SCHEMBL1681816 | 0.78 | ALDH1A1 (0.60) | ACHE | |
| Bromide SCHEMBL1681744 | 0.78 | ALDH1A1 (0.60) | ACHE | |
| SCHEMBL1682046 | 0.77 | CCR3 (0.59) | — | |
| SCHEMBL1682002 | 0.76 | SLC6A12 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305645-B1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA PHARMA CORP (CN) | 2012-05-16 | — | — | EP | claimed |
| US-20110105503-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA PHARMA. CORPORATION (CN) | 2011-05-05 | — | — | US | claimed |
| EP-2305645-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA Pharma.corporation (CN) | 2011-04-06 | — | — | EP | claimed |
| US-8501778-B2 | Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent | NHWA PHARMA. CORPORATION (CN) | 2013-08-06 | — | — | US | disclosed |
| EP-2305645-B1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA PHARMA CORP (CN) | 2012-05-16 | — | — | EP | disclosed |
| US-20110105503-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA PHARMA. CORPORATION (CN) | 2011-05-05 | — | — | US | disclosed |
| EP-2305645-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA Pharma.corporation (CN) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105503-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | ADK, AAK1, ATAD5 | ACHE 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.